ACROBiosystems

CD19 has long been considered a “gold-standard target” in CAR-T therapy, with its highly restricted expression pattern and prevalence across B-cell malignancies making it an ideal target for immune-based therapies. Yet even well-validated targets come with challenges. What are the key biological limitations of CD19-targeted CAR-T therapy? And what alternative strategies could help overcome them? Explore the biology, limitations, and evolving strategies surrounding CD19 as a CAR-T target.

As CAR-T therapy continues to evolve, optimizing the targeting domain has become a key focus for next-generation cell therapies. While scFvs remain the most widely used CAR binders, VHHs (nanobodies) are emerging as a promising alternative, offering unique advantages and gaining increasing clinical recognition.

📢 Live Webinar: Exploring New Frontiers in In Vivo CAR-T Therapy Join our upcoming webinar, “Exploring New Frontiers in In Vivo CAR-T Therapy,” and hear from two experts on the latest advances in in vivo CAR-T development. Featured Talk 1 - Joe Yu, PhD Targeted-LNP Technology for Precision Genetic Medicine Featured Talk 2 - Hui Yu, PhD From Delivery Vehicle to Cells: Enabling In Vivo CAR Development with Integrated End-to-End Solutions 📅 Date: Sept 15, 2026 ⏱ Time: 10 AM PT | 1 PM ET | 5 PM GMT | 7 PM CET Explore practical strategies to advance in vivo CAR-T development, from targeted LNP design and delivery optimization to sensitive CAR detection and evaluation. Gain insights into key challenges and solutions across the development workflow—from early-stage discovery to translational research.

When precision is critical and samples are limited, inefficient workflows can slow even the most advanced projects. Discover a smarter, faster approach with TR-FRET—designed to improve screening efficiency, reduce sample consumption, and deliver reliable results. Join Dr. Llama to explore how you can streamline your workflow and achieve better screening outcomes. 👉 Learn more and accelerate your screening process.

Your Audit-Ready Partner: Passed by 20+ Global Pharma Audits. Are you next? In the world of GMP, “good enough” is never enough. Compliance is the foundation of patient safety and your regulatory success. From ISO 9001 and 13485 to the rigorous Rx360 and MDSAP certifications, our quality management system is built to meet—and exceed—global standards (FDA, EMA, NMPA). We don’t just stay “ready” for audits; we live them every day. Get an inside look at our QC labs and data integrity protocols. Secure your peace of mind on April 8th! Join our GMP Open Day Global Session :)

Hello, are you seeking innovative solutions in Biotechnology Research? Discover how ACROBiosystems partners with global leaders like Pfizer and Novartis, offering variety of high-quality products and services for biopharmaceutical advancements.